BR112012033344B1 - Composto de quinazolina, composição farmacêutica, método in vitro para inibir a superexpressão e/ou hiperatividade do receptor do fator de crescimento epidérmico e uso do composto - Google Patents
Composto de quinazolina, composição farmacêutica, método in vitro para inibir a superexpressão e/ou hiperatividade do receptor do fator de crescimento epidérmico e uso do composto Download PDFInfo
- Publication number
- BR112012033344B1 BR112012033344B1 BR112012033344-5A BR112012033344A BR112012033344B1 BR 112012033344 B1 BR112012033344 B1 BR 112012033344B1 BR 112012033344 A BR112012033344 A BR 112012033344A BR 112012033344 B1 BR112012033344 B1 BR 112012033344B1
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- compound
- pharmaceutically acceptable
- acceptable salt
- fact
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2010/074792 | 2010-06-30 | ||
| PCT/CN2010/074792 WO2012000182A1 (en) | 2010-06-30 | 2010-06-30 | Quinazoline compounds |
| PCT/CN2011/074637 WO2012000356A1 (en) | 2010-06-30 | 2011-05-25 | Quinazoline compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012033344A2 BR112012033344A2 (pt) | 2016-11-29 |
| BR112012033344B1 true BR112012033344B1 (pt) | 2020-12-15 |
Family
ID=45401313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012033344-5A BR112012033344B1 (pt) | 2010-06-30 | 2011-05-25 | Composto de quinazolina, composição farmacêutica, método in vitro para inibir a superexpressão e/ou hiperatividade do receptor do fator de crescimento epidérmico e uso do composto |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9168253B2 (pt-PT) |
| EP (1) | EP2590966B1 (pt-PT) |
| JP (1) | JP5736452B2 (pt-PT) |
| KR (1) | KR101480481B1 (pt-PT) |
| AU (1) | AU2011274183B2 (pt-PT) |
| BR (1) | BR112012033344B1 (pt-PT) |
| CA (1) | CA2801814C (pt-PT) |
| DK (1) | DK2590966T3 (pt-PT) |
| ES (1) | ES2604929T3 (pt-PT) |
| HK (1) | HK1179954A1 (pt-PT) |
| HR (1) | HRP20161490T1 (pt-PT) |
| HU (1) | HUE029801T2 (pt-PT) |
| LT (1) | LT2590966T (pt-PT) |
| MX (1) | MX2012015047A (pt-PT) |
| MY (1) | MY172201A (pt-PT) |
| PL (1) | PL2590966T3 (pt-PT) |
| PT (1) | PT2590966T (pt-PT) |
| RS (1) | RS55470B1 (pt-PT) |
| RU (1) | RU2530887C2 (pt-PT) |
| SG (1) | SG186410A1 (pt-PT) |
| SI (1) | SI2590966T1 (pt-PT) |
| WO (2) | WO2012000182A1 (pt-PT) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092289A1 (es) | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
| WO2018099451A1 (zh) * | 2016-12-01 | 2018-06-07 | 和记黄埔医药（上海）有限公司 | 化合物的晶型 |
| KR101957464B1 (ko) | 2018-10-18 | 2019-03-12 | 대흥전력기술 주식회사 | 활선 상태에서 지상기기의 점검 및 누유 보수방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CN101619043B (zh) * | 2008-06-30 | 2013-06-05 | 和记黄埔医药（上海）有限公司 | 喹唑啉衍生物及其医药用途 |
| US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
-
2010
- 2010-06-30 WO PCT/CN2010/074792 patent/WO2012000182A1/en active Application Filing
-
2011
- 2011-05-25 PL PL11800101T patent/PL2590966T3/pl unknown
- 2011-05-25 ES ES11800101.5T patent/ES2604929T3/es active Active
- 2011-05-25 HU HUE11800101A patent/HUE029801T2/en unknown
- 2011-05-25 MX MX2012015047A patent/MX2012015047A/es active IP Right Grant
- 2011-05-25 WO PCT/CN2011/074637 patent/WO2012000356A1/en active Application Filing
- 2011-05-25 EP EP11800101.5A patent/EP2590966B1/en active Active
- 2011-05-25 AU AU2011274183A patent/AU2011274183B2/en not_active Ceased
- 2011-05-25 MY MYPI2012005682A patent/MY172201A/en unknown
- 2011-05-25 RS RS20160973A patent/RS55470B1/sr unknown
- 2011-05-25 LT LTEP11800101.5T patent/LT2590966T/lt unknown
- 2011-05-25 KR KR20137001865A patent/KR101480481B1/ko active IP Right Grant
- 2011-05-25 SI SI201131012A patent/SI2590966T1/sl unknown
- 2011-05-25 US US13/807,460 patent/US9168253B2/en not_active Expired - Fee Related
- 2011-05-25 DK DK11800101.5T patent/DK2590966T3/en active
- 2011-05-25 SG SG2012093779A patent/SG186410A1/en unknown
- 2011-05-25 BR BR112012033344-5A patent/BR112012033344B1/pt not_active IP Right Cessation
- 2011-05-25 JP JP2013516973A patent/JP5736452B2/ja not_active Expired - Fee Related
- 2011-05-25 RU RU2012153174/04A patent/RU2530887C2/ru active
- 2011-05-25 PT PT118001015T patent/PT2590966T/pt unknown
- 2011-05-25 CA CA2801814A patent/CA2801814C/en not_active Expired - Fee Related
-
2013
- 2013-06-18 HK HK13107098.1A patent/HK1179954A1/xx not_active IP Right Cessation
-
2016
- 2016-11-11 HR HRP20161490TT patent/HRP20161490T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG186410A1 (en) | 2013-01-30 |
| AU2011274183A1 (en) | 2013-01-10 |
| HUE029801T2 (en) | 2017-04-28 |
| SI2590966T1 (sl) | 2016-12-30 |
| HRP20161490T1 (hr) | 2016-12-16 |
| MY172201A (en) | 2019-11-15 |
| US20130172373A1 (en) | 2013-07-04 |
| PT2590966T (pt) | 2016-11-29 |
| EP2590966A1 (en) | 2013-05-15 |
| LT2590966T (lt) | 2016-11-25 |
| RU2530887C2 (ru) | 2014-10-20 |
| WO2012000182A1 (en) | 2012-01-05 |
| US9168253B2 (en) | 2015-10-27 |
| HK1179954A1 (en) | 2013-10-11 |
| BR112012033344A2 (pt) | 2016-11-29 |
| WO2012000356A1 (en) | 2012-01-05 |
| MX2012015047A (es) | 2013-02-07 |
| AU2011274183B2 (en) | 2013-09-26 |
| JP2013529653A (ja) | 2013-07-22 |
| ES2604929T3 (es) | 2017-03-10 |
| CA2801814C (en) | 2015-04-07 |
| EP2590966B1 (en) | 2016-08-31 |
| PL2590966T3 (pl) | 2017-05-31 |
| KR101480481B1 (ko) | 2015-01-09 |
| KR20130031358A (ko) | 2013-03-28 |
| CA2801814A1 (en) | 2012-01-05 |
| RU2012153174A (ru) | 2014-08-10 |
| DK2590966T3 (en) | 2016-12-19 |
| JP5736452B2 (ja) | 2015-06-17 |
| EP2590966A4 (en) | 2014-01-15 |
| RS55470B1 (sr) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2667706T3 (es) | Compuesto de diamino-carboxamida heterocíclica | |
| KR102618773B1 (ko) | 디아릴 거대환형 화합물을 수반하는 병용 요법 | |
| RU2316326C2 (ru) | Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины | |
| EP3025716B1 (en) | Substance for treatment or relief of pain | |
| BRPI0805826B1 (pt) | compostos espiro-substituídos, composição farmacêutica e uso | |
| BRPI0908635B1 (pt) | Composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
| BRPI0908675B1 (pt) | Composto e composição farmacêutica | |
| TWI726363B (zh) | Fak/alk/ros1抑制劑與egfr抑制劑的組合治療癌症的方法 | |
| JP2016538281A (ja) | 血液脳関門を通過するタンパク質ホスファターゼ阻害剤 | |
| JP2019522037A (ja) | インドリノン化合物の使用 | |
| BR112020023204A2 (pt) | composições que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso dos mesmos | |
| WO2015035410A1 (en) | Cancer therapy | |
| BR112012033344B1 (pt) | Composto de quinazolina, composição farmacêutica, método in vitro para inibir a superexpressão e/ou hiperatividade do receptor do fator de crescimento epidérmico e uso do composto | |
| CN102906086B (zh) | 喹唑啉化合物 | |
| TWI466888B (zh) | 喹唑啉化合物 | |
| RU2784853C2 (ru) | Комбинационная терапия с применением диарильных макроциклических соединений | |
| US10512631B2 (en) | Chalcone compounds | |
| TW201202240A (en) | Quinazoline compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2724 DE 21-03-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |